TIC10
Mitochondrial caseinolytic protease P activator / Anticancer agent / TIC10 (1616632-77-9) is novel anti-cancer compound that acts via early-stage integrated stress response activation leading to selective cancer cell death.1-3 TIC10 potently activates mitochondrial caseinolytic protease P (ClpP) causing eIF2α-independent induction of ATF4 and Akt/ERK/Foxo3a/DR5/TRAIL-dependent apoptosis.4 Currently in clinical trials.
Biochemicals & reagents
1616632-77-9
ONC201
1) Allen et al. (2013) Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects, Sci. Transl. Med. 5 171ra17 2) Allen et al. (2015) Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway, Mol. Cancer. 14 99 3) Allen et al. (2016) Discovery and Clinical Introduction of First-In-Class Imipridone ONC201, Oncotarget 7 74380 4) Ishizawa et al. (2019) Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality, Cancer Cell 35 721
-20°C
TARGET: Protease -- PATHWAY: AKT; Mitochondrial function -- RESEARCH AREA: Cellular stress; Cell death -- DISEASE AREA: Cancer